KRAS-Targeting Drugs Show Promise for Rare Appendix Cancer
Targeting mutant KRAS may offer a promising new treatment option for appendix cancer, according to research from The University of Texas MD Anderson Cancer Center published in the Journal of…
Read the full articleYou might also wanna read
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM
Results of the earlier phase 1-2 study of 168 patients, published recently 🧪💊
New cancer drug trial offers hope for patients with rare aggressive tumour
Hope has been offered to patients living with a rare and aggressive form of cancer.
Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds
An experimental pill helped people with one of the most deadly cancers in the world live longer, researchers reported this weekend.
fox26houston.com·1mo ago
Combination therapy with RAS inhibitors shows promise for pancreatic cancer regression and resistance prevention
Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest cancer survival rates. Recent studies using RAS inhibitors have opened the doo
pnas.org·1mo ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre
chicagotribune.com·1mo agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre
chicagotribune.com·1mo ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer patients
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre
chicagotribune.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.